Miletus’ Business & Corporate Development team brings decades of experience and hundreds of executed deals to every engagement. We support clients across the full deal lifecycle—from asset positioning and partner outreach to term sheet negotiation and transaction execution. Our expertise spans university out-licensing, pharma in- and out-licensing, portfolio strategy, risk modeling, and deal structuring. Whether you’re a startup seeking your first partner or an established company optimizing a portfolio, we provide strategic and practical guidance to help you build value and close the right deals.

Miletus helps clients unlock the value of their intellectual property through targeted monetization strategies and hands-on execution. We support companies, investors, and institutions in identifying valuable IP assets, assessing commercial potential, and developing licensing, enforcement, or divestiture strategies. Our team brings deep experience in evaluating patent portfolios, structuring royalty or milestone-driven deals, and supporting litigation financing and licensing campaigns. Miletus will work alongside legal counsel to turn IP into a business asset that drives returns.

Miletus partners with universities, hospitals, and government institutions to help translate scientific innovation into real-world impact. In a rapidly evolving regulatory and funding environment, we help institutions navigate complexity with creative, customized solutions that align with their mission and structure. Our team works alongside tech transfer offices, innovation teams, and research leadership to support licensing, startup formation, and strategic partnerships—always tailoring our approach to the unique challenges and opportunities each institution faces. We bring practical experience and flexible thinking to accelerate the path from discovery to delivery.

Access world-class leadership without full-time costs. Our network of fractional executives—CEOs, COOs, CFOs, CMOs, and CTOs—provides the experienced infrastructure your startup needs to navigate biotech's complexities while maintaining focus on innovation.

We believe traditional capitalization model works poorly in biotech. We help our portfolio companies access capital creatively, through our network of alternative capital providers. We also serve as fractional Investment Officer for patient and non-profit organization endowments and Family Offices, bringing capital, strategic insights and access to their infrastructure to the benefit of our companies.

Early-stage biotech faces unique challenges. Our advisory services draw from decades of company-building experience, offering practical guidance on everything from regulatory strategy to team development. We've been where you're going—let us help you get there faster.